This research review examined the safety and efficacy evidence for peptide therapies used in musculoskeletal injuries and athletic performance, including BPC-157, finding limited clinical data to support many commonly used peptides. For medical practitioners selling peptide supplements, this highlights the importance of understanding the current evidence gaps and managing patient expectations regarding outcomes. For Annular and similar brands offering oral peptides to clinics, this research underscores the need for transparent communication about the preliminary nature of much peptide research when educating healthcare providers about their products.
For your business
BPC-157 demonstrates gastric cytoprotective properties and may influence angiogenesis and tissue repair pathways through interactions with growth factor signaling. This mechanism suggests potential applications in supporting tissue healing processes, though clinical evidence in humans remains limited compared to preclinical studies.